Advice
Following a full submission.
Rabeprazole is accepted for use within NHS Scotland for on-demand symptomatic treatment of moderate to severe gastro-oesophageal reflux disease (GORD) in patients without oesophagitis.
It is the second proton-pump inhibitor (PPI) with a specific licence for on-demand therapy.
Provided that there is a clearly defined need for maintenance therapy following acute treatment of GORD and that rabeprazole is considered to be the most appropriate PPI, ondemand use of rabeprazole is an effective treatment option in patients without oesophagitis.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- Rabeprazole (Pariet®)
- SMC ID:
- 118/04
- Indication:
- Moderate to very severe gastro-oesophageal reflux disease
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 September 2004